

1 **Seroprevalence, Knowledge, Attitudes, and Practices of People to COVID-19 in**  
2 **Chililabombwe and Lusaka Districts of Zambia.**

3 Mercy Sampa<sup>1\*</sup>, Joyce Siwila<sup>2</sup>, Bernard Hangómbé<sup>1,3</sup>, Gerald Misinzo<sup>4</sup>, Mark Rweyemamu<sup>4</sup>,  
4 Chisanga Chipanta<sup>5</sup> and Martin C. Simuunza<sup>1,6</sup>

5 1 Africa Centre of Excellence for Infectious Diseases of Humans and Animals, University of  
6 Zambia, Lusaka, Zambia

7 2 Department of Clinical Studies, School of Veterinary Medicine, University of Zambia,  
8 Lusaka, Zambia

9 3 Department of Paraclinical Studies, School of Veterinary Medicine, University of Zambia,  
10 Lusaka, Zambia.

11 4 SACIDS Africa Centre of Excellence for Infectious Diseases, Sokoine University of  
12 Agriculture, Morogoro, Tanzania

13 5 Department of Biomedical Sciences, School of Veterinary Medicine, University of Zambia,  
14 Lusaka, Zambia.

15 6 Department of Disease Control, School of Veterinary Medicine, University of Zambia,  
16 Lusaka, Zambia

17 \* Corresponding author

18

## 19 **Abstract**

20 Coronavirus disease 2019 (COVID-19) is a respiratory disease caused by the severe acute  
21 respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first reported in Wuhan, China.  
22 Understanding seroprevalence and the knowledge, attitudes and practices (KAP) of individuals  
23 in a given context is crucial for effective public health interventions. This cross-sectional study  
24 assessed the seroprevalence of SARS-CoV-2 antibodies and KAP toward COVID-19 in  
25 Chililabombwe and Lusaka districts of Zambia. A total of 179 participants were enrolled in the  
26 study. These included individuals who visited a health facility, were 18 years of age or older,  
27 and were residents of the selected districts. Each participant was swabbed with one  
28 nasopharyngeal sample by the medical officer present and immediately subjected to a COVID-  
29 19 rapid diagnostic test using the Sure Status® kit (Premier Medical Corporation) targeting the  
30 nucleocapsid protein antigen from SARS-CoV-2. In addition, Samples were collected from  
31 these participants by drawing approximately 5 ml of venous blood, and the extracted sera was  
32 subjected to ELISA targeting the SARS-CoV-2 Nucleocapsid protein. A semi structured  
33 questionnaire was used to collect demographic and KAP data from the participants. Only one  
34 positive case was detected using the rapid diagnostic test (RDT) 0.5% (1/179). The overall  
35 seroprevalence of COVID-19 antibodies in the study areas was 9.5% (17/179). The  
36 seroprevalence in Chililabombwe (11.0%) was higher than that in Lusaka (8.0%). The study  
37 found variations in seroprevalence based on age, gender, and education level, with higher rates  
38 among individuals aged 40-49, females and those with no education. However, these  
39 differences were not statistically significant ( $p > 0.05$ ). Both seropositive and seronegative  
40 participants exhibited moderate knowledge and attitudes, alongside high levels of preventive  
41 practices, indicating a shared understanding of health risks and practices. Further analysis  
42 showed that low knowledge, attitudes and practices were strongly associated with higher  
43 seropositivity. This study recommends enhanced community engagement in future pandemics

44 to close knowledge gaps, disseminate accurate information, and promote effective preventive  
45 behaviours. These efforts could help limit the spread of diseases and strengthen community  
46 resilience in response to pandemics.

47 **Keywords:** COVID-19, Seroprevalence, Knowledge, Attitudes, Practices, Zambia, SARS-  
48 CoV-2.

## 49 **Introduction**

50 Coronavirus disease 2019 (COVID-19) is a respiratory disease caused by the severe acute  
51 respiratory syndrome coronavirus 2 (SARS-CoV-2) (Agrahari *et al.*, 2021). The disease,  
52 (COVID-19), was first reported in Wuhan, China, in December 2019 (Khan, 2020). The  
53 principal route of transmission is either through inhalation of airborne droplets exhaled by  
54 infected individuals or direct contact of these droplets with the eyes, nose, or mouth (Wei *et*  
55 *al.*, 2020). Through its spike (S) protein structure, the virus gains entry into the host by  
56 attaching to the angiotensin-converting enzyme 2 (ACE2) receptors on the surface of human  
57 cells. This facilitates its entry into host cells, particularly those in the respiratory system  
58 (Theodore *et al.*, 2023). The virus causes similar symptoms to severe acute respiratory  
59 syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome (MERS-CoV)  
60 which usually begin to show two weeks after infection (Kontou, 2020). These include fever,  
61 respiratory problems or breathlessness, fatigue, muscle aches, reduced ability to taste or smell,  
62 headaches, and sensations of nausea or vomiting (Adam *et al.*, 2022). However, COVID-19  
63 disease has the potential to result in serious complications like kidney failure, severe  
64 pneumonia, acute respiratory syndrome, and fatality (Wei *et al.*, 2020).

65 The diagnosis of COVID-19 includes molecular tests, antigen tests and serological tests. Low  
66 and middle-income countries usually utilize the antigen rapid diagnostic test (Ag RDT) because  
67 of its low cost. This is done through a nasopharyngeal swab (Jacobs *et al.*, 2020). However,

68 the most dependable method for detecting SARS-CoV-2 currently is via real-time reverse  
69 transcription polymerase chain reaction (RT-PCR). This technique pinpoints distinct genetic  
70 sequences of the virus, confirming its presence in samples collected from the upper respiratory  
71 tract (Mesina *et al.*, 2021). Serological laboratory examinations identify SARS-CoV-2  
72 antibodies within blood samples, these are quite simple to perform and easy to use for screening  
73 (Daka, 2014; Rubegwa, 2015).

74 The epidemiological landscape of COVID-19 in Zambia has been relatively well-defined  
75 (WHO, 2023). The Ministry of Health (MOH) reported the first COVID-19 case in March  
76 2020, and as of August 17<sup>th</sup>, 2023, the country had seen approximately 349,287 confirmed  
77 cases and 4,069 deaths. (National Public Health Institute, 2022) However, given that Zambia  
78 still faces limitations in its testing capacity, the actual number of people exposed to the disease  
79 may be underestimated (Adam *et al.*, 2022). The combined measured prevalence of SARS-  
80 CoV-2 was found to be 10.6% (95% CI of 7.3-13.9). The researchers concluded that the actual  
81 number of SARS-CoV-2 infections might surpass the officially recorded count in these six  
82 districts, emphasizing the importance of early isolation of infected individuals and timely  
83 identification of their contacts (Mulenga *et al.*, 2021).

84 Various factors, including socioeconomic status, test kit availability, and proximity to the  
85 nearest healthcare facility, could impact an individual's capacity to undergo testing. This can  
86 lead to underreporting of the prevalence of the disease in the country. However, the  
87 identification of anti-SARS-CoV-2 antibodies through serological assays may aid in  
88 approximating the number of individuals who may have been exposed to the infection.

89 Understanding the knowledge, attitudes, and practices (KAP) among individuals concerning  
90 COVID-19 can facilitate the development of targeted prevention and control strategies (Ugwu  
91 *et al.*, 2020). Several studies have explored public KAP towards COVID-19 across different

92 settings, highlighting how these factors influence the success of public health responses (e.g.,  
93 Zhong et al., 2020; Reuben et al., 2021). In Zambia, however, there's limited data linking KAP  
94 to actual exposure to the virus, especially in high-traffic or border areas. The main goal of this  
95 study was to determine the seroprevalence of antibodies to SARS-CoV-2 in adults and  
96 investigate their knowledge, attitudes, and practices of COVID-19 in Chililabombwe and  
97 Lusaka district of Zambia.

## 98 **Materials and Methods**

### 99 **Study Area**

100 The study was conducted among residents of Lusaka and Chililabombwe districts in Zambia  
101 (Figure 1). These districts were purposefully selected due to their strategic roles as transit hubs  
102 and their geographical location within provinces reporting the highest cumulative COVID-19  
103 cases in the country (Ministry of Health, 2023). Lusaka and Chililabombwe districts are both  
104 urban areas with populations of 2,567,093 and 124,577, respectively (Central Statistics  
105 Agency, 2022). Chililabombwe, a major border town with the Democratic Republic of Congo,  
106 hosts one of Zambia's largest cross-border markets. Meanwhile, Lusaka is home to Kenneth  
107 Kaunda International Airport, the country's largest and busiest airport. According to Ministry  
108 of Health data from 2023, Lusaka Province recorded a total of 94,242 COVID-19 cases, while  
109 Copperbelt Province reported 47,795 cases out of the 349,287 at country total.

### 110 **Ethics approval and consent to participate**

111 The study was approved by Excellence in Research Ethics and Science (ERES) CONVERGE  
112 IRB (Reg No.2022-June-014) and the National Health Research Authority (NHRA) (Reg No.  
113 20 NHRA000003/19/01/2023). Further permission was sought from the Ministry of Health and  
114 authorization to enter health facilities was obtained from the Provincial Health Office, District  
115 Health Offices and personnel in-charge of each health facility. Informed consent was sought

116 from all those that agreed to participate in the study and information collected from the  
117 participants was used only for research purposes. Confidentiality of personal information was  
118 upheld throughout the study by ensuring that participants' information was anonymous and  
119 identities withheld.

### 120 **Study design and sampling**

121 This study was cross-sectional in design. The sample size was determined using the formula  
122 recommended by Charan and Biwas (2013) assuming a SARS-CoV-2 prevalence of 13.5% in  
123 Zambia (Shanaube *et al.*, 2022), a 95% confidence level and a 5% absolute error. The resulting  
124 sample size calculation was estimated to be 179 participants. This study included individuals  
125 who visited a health facility, were 18 years of age or older, residing in the district of interest,  
126 were willing, and provided consent to participate in the research. Each participant was swabbed  
127 with one nasopharyngeal sample by the medical officer present and immediately subjected to  
128 a COVID-19 rapid diagnostic test using the Sure Status® kit (Premier Medical Corporation)  
129 targeting the nucleocapsid protein antigen from SARS-CoV-2. In addition, blood samples were  
130 collected from the participants by drawing approximately 5 ml of venous blood samples from  
131 either the median cubital or cephalic vein and placed into plain vacutainers. After sample  
132 collection, a structured questionnaire was administered to each participant to collect  
133 information on demographics, COVID-19 symptoms, household COVID-19 cases, perception  
134 of COVID-19 infection risk; adherence to recommended prevention measure, knowledge,  
135 attitudes and practices regarding COVID-19.

### 136 **Sample processing and analysis**

137 The collected blood samples were left overnight and centrifuged the following day at 1500 rpm  
138 for 10 minutes. The resulting serum was harvested and stored at -20°C in compliance with  
139 cold-chain protocols. They were subsequently transported to the University of Zambia, School

140 of Veterinary Medicine Public Health laboratory on ice. The Invitrogen™ Human SARS-CoV-  
141 2 N Enzyme-linked Immuno-Sorbent Assay (ELISA) (Thermo Fisher catalogue number  
142 EH490 RB) targeting the nucleocapsid protein was used to detect antibodies to SARS-Cov-2,  
143 according to the manufacturer's instructions. Optical density (OD) readings were taken at 450  
144 nm using a Multiskan™ FC Microplate Photometer (Thermo Fisher Scientific, USA). Sample  
145 results were interpreted based on the manufacturer's recommended cut-off values: samples  
146 with OD values above the cut-off were considered positive, while those below were classified  
147 as negative.

## 148 **Data analysis**

149 Data were entered into Microsoft Excel and statistical analyses were conducted using IBM  
150 SPSS Statistics version 26 (SPSS Inc., Chicago IL, USA) and GraphPad Prism 9.0 (GraphPad  
151 Software, Boston, Massachusetts USA). Seroprevalence was determined as the proportion of  
152 individuals with a positive test result for the total antibodies. The Pearson Chi-squared ( $X^2$ ) test  
153 or the Fisher's Exact test, where appropriate were used to examine associations between  
154 sociodemographic factors and seropositivity.

155 The participants' KAP were assessed by summing the correct responses, from which the mean  
156 score was calculated. Participants responded with "Yes" or "No," with correct answers scoring  
157 1 and incorrect answers scoring 0. The KAP levels were categorised as high, moderate, or low  
158 based on predetermined thresholds using Bloom's cut-off criteria (Hasan et al., 2022)  
159 According to these criteria, scores above 60 indicated a high level of KAP, scores between 25  
160 and 59 represent moderate levels, and scores below 25 suggest a low level. All statistics were  
161 considered significant at a  $p \leq 0.050$ .

## 162 **Results**

### 163 **Characteristics of study participants and seroprevalence of SARS-CoV-2**

164 Of the 179 participants, 88 (49.2%) were male (Table 1). A total of 84 respondents (46.9%)  
165 were aged between 18 and 29 years, representing the largest age group in the study. The  
166 smallest age group comprised individuals above 50 years, with 15 respondents (8.4%) in this  
167 category. In terms of marital status, the majority (57.5%) were single, followed by 66  
168 participants (36.9%) who reported being married.

169 The majority (53.6%) of the respondents reported secondary education as the highest level of  
170 education they had attained while 5.6% of the respondents had no formal education. About  
171 52.0% were employed, and participants were evenly distributed between the two districts, with  
172 50.8% from Chililabombwe district (Table 1).

173 Only one positive case was detected using the rapid diagnostic test (RDT). However, ELISA  
174 testing, revealed an overall SARS-CoV-2 antibody seroprevalence of 9.5% (95% CI: 6.0–14.7)  
175 (Table 1). Chililabombwe recorded a higher seroprevalence of 11.0% (95% CI: 6.1–19.1),  
176 compared to 8.0% (95% CI: 3.9–15.5) in Lusaka. Variations in SARS-CoV-2 seropositivity  
177 were observed across demographic variables such as age group, sex, marital status, education  
178 level, and employment status (Table 1). Apart from lack of formal education, no other  
179 demographic variable showed a statistically significant association with SARS-CoV-2  
180 seropositivity in the two districts (Table 1).

## 181 **Knowledge, attitudes and practices of study participants and seroprevalence of COVID-** 182 **19**

183 Out of the 179 respondents (both seropositive and seronegative for COVID-19), 95.5%  
184 reported that they had heard of COVID-19. Among those who were aware, 9.4% were  
185 seropositive, while 90.6% were seronegative. The remaining 4.5% had no prior awareness of  
186 the disease. The source of information regarding COVID-19 was investigated in this study.  
187 Respondents from both the seropositive and seronegative groups indicated that they received

188 information about COVID-19 through various sources (Figure 4), with the majority relying on  
189 friends, family, and colleagues. Other sources included TV/Radio, social media, health  
190 workers, newspapers, religious leaders, and teachers. Both seropositive and seronegative  
191 participants identified the common COVID-19 symptoms, including cough, runny nose, and  
192 fever. They understood close contact as the main mode of transmission, though fewer  
193 recognized airborne droplets. Most believed that COVID-19 was curable, mainly by seeking  
194 help from healthcare facilities, while a few mentioned herbal remedies or prayer. Overall, both  
195 seropositive and seronegative groups showed moderate knowledge of COVID-19 (Table 3).

196 The study found that participants who had low knowledge about COVID-19 had the highest  
197 seropositivity 20% followed by those with high knowledge (16.3%) and moderate knowledge  
198 (2.9%) (Table 2). The association between knowledge levels and seropositivity was statistically  
199 significant ( $p = 0.003$ ) (Table 2).

200 Seropositive individuals with low attitude scores had the highest seropositivity rate at (22.2%),  
201 compared to (9.8%) among those with high attitude scores and (3.2%) for moderate attitudes.  
202 (Table 2). This trend suggested that individuals with a poorer attitude towards COVID-19  
203 prevention measures were more likely to have been exposed to the virus.

204 A Similar pattern was found in practice scores: participants with low adherence to preventive  
205 practices had a seroprevalence of (40%), compared to (10.5%) for those with high practice  
206 levels and (6.3%) for moderate (Table 2). This pattern indicated variations in infection rates  
207 based on the level of preventive practices adopted. There was a significant association between  
208 individuals' practices and their likelihood of testing positive for SARS-CoV-2 ( $p = 0.002$ ).

209 Despite similar emotional responses to COVID-19 both those who tested seropositive and those  
210 who tested seronegative for SARS-CoV-2 believed they could get COVID-19 including

211 embarrassment, fear, and sadness (Table 4). Both groups primarily feared death and isolation,  
212 and most seropositive participants sought emotional support from doctors or family

213 The findings in Table 5 indicate that a majority of respondents consistently followed mask-  
214 wearing guidelines in public places. Most (52.94%) of the participants followed hand-washing  
215 practices. Furthermore, an overwhelming majority (88.2%) consistently avoided large  
216 gatherings. The average scores indicated high adherence to COVID-19 preventive practices in  
217 both the seropositive and seronegative participants (Table 5).

## 218 **Discussion**

219 Coronavirus disease 2019 (COVID-19) has impacted countries globally, with varying degrees  
220 of disease burden and social economic disruptions, prompting various levels of responses to  
221 the disease. This study aimed to estimate the prevalence of SARS-CoV-2 antibodies using both  
222 rapid diagnostic tests (RDTs) and ELISA. While the RDT detected only one positive case out  
223 of 179 participants, ELISA revealed a seroprevalence of 9.5%. The prevalence from the RDT  
224 was much lower than that of ELISA because RDTs detected active infection by identifying  
225 viral antigens and had lower sensitivity, especially in individuals with low viral loads or during  
226 the later stages of infection (Mak et al., 2020; Peeling et al., 2021). ELISA, on the other hand,  
227 detected a higher number of participants who were positive to SARS-CoV 2 antibodies,  
228 indicating prior exposure, making it more reliable for assessing cumulative exposure in the  
229 population. The markedly lower prevalence detected by RDTs compared to ELISA could be  
230 attributed to their lower sensitivity in detecting active infection, particularly among  
231 asymptomatic individuals, those with low viral loads, or in the later stages of infection as the  
232 antigen levels declined (Dinnes et al., 2021; Peeling et al., 2021). In contrast, ELISA detects  
233 antibodies that persist after infection, making it a more reliable method for assessing  
234 cumulative exposure in the population. Similar findings were reported in studies from

235 Mozambique (Arnaldo et al., 2022), Nigeria (Reuben et al., 2021), and Ethiopia (Aynalem et  
236 al., 2021), where serological assays demonstrated significantly higher prevalence rates than  
237 RDTs, highlighting the limitations of relying solely on antigen-based tests for accurate  
238 population-level surveillance in African settings.

239 Chililabombwe recorded a slightly higher seropositivity than Lusaka, a difference that may be  
240 attributed to factors such as socioeconomic conditions, cross border activities, healthcare  
241 infrastructure, and access to testing services. Similar disparities in seroprevalence have been  
242 reported elsewhere. For instance, studies in Mozambique and the United States of America  
243 linked regional variations in infection rates to differences in healthcare infrastructure and  
244 socioeconomic status (Naiyer et al., 2021; Hatef et al., 2020).

245 A higher prevalence was observed among individuals aged 18-29, suggesting that younger  
246 adults may have been more socially active, thus increasing their risk of exposure. This aligns  
247 with research in Mozambique, where older adults ( $\geq 55$  years) showed greater adherence to  
248 preventive measures due to perceived vulnerability (Arnaldo et al., 2022). Although females  
249 had higher seroprevalence than males in this study, the difference was not statistically  
250 significant. This finding is consistent with a systematic review in Africa, which found no clear  
251 link between gender and antibody presence (Chisale et al., 2021), and the WHO's neutral stance  
252 on gender in COVID-19 health planning (WHO, 2022).

253 Among all assessed factors, lack of formal education and moderate attitude levels were  
254 significantly associated with higher seropositivity. Individuals with no formal education may  
255 have limited health literacy, hindering their ability to understand or act on public health  
256 information (Smith et al., 2020). Interestingly, individuals with moderate attitude scores  
257 demonstrated lower seropositivity than those with low scores. This pattern may indicate that a  
258 moderate level of concern—striking a balance between complacency and alarm—could be

259 linked to more consistent adherence to protective behaviours. However, further investigation  
260 is warranted to better understand this relationship (Jones et al., 2021).

261 In line with previous studies (Zhong et al., 2020; Aynalem et al., 2021), this study found that  
262 low knowledge, low attitude, and low practice scores were associated with increased risk of  
263 SARS-CoV-2 exposure. Participants with low KAP scores were more likely to test positive,  
264 reinforcing the need for targeted health education and behavioural interventions to improve  
265 knowledge, attitudes, and practices within the community. Participants demonstrated a  
266 reasonable understanding of COVID-19's cause, symptoms, and primary transmission  
267 methods. These findings mirror earlier research (Zhong et al., 2020; Clements, 2020), which  
268 attributed public awareness to effective health communication. However, misconceptions  
269 remained. While most recognized close contact as a key transmission route, fewer participants  
270 identified handshakes and airborne droplets—consistent with findings by Geldsetzer (2020).  
271 Although many believed COVID-19 could be cured, often relying on healthcare providers, few  
272 cited herbal remedies or prayer. This reliance on medical professionals reflects public trust in  
273 health systems, even amid uncertainty.

274 Information about COVID-19 was accessed through diverse sources, including health workers,  
275 family, friends, radio/TV, religious leaders, and newspapers. This highlights the importance of  
276 leveraging multiple communication channels in public health messaging. Health professionals,  
277 in particular, were viewed as trusted figures (Schiavo, 2014), underscoring their central role in  
278 effective information dissemination. Likewise, religious leaders and health educators were  
279 noted as influential sources due to their embedded roles in communities (Berkley, 2020; Basch  
280 et al., 2020).

281 The study also found that many participants acknowledged their susceptibility to COVID-19,  
282 expressing a range of emotions such as fear, sadness, and concern, similar to findings by  
283 Geldsetzer (2020) and Reuben et al. (2021). Despite this emotional response, the moderate

284 average attitude scores suggest a general acceptance of the disease’s presence and seriousness  
285 in the communities studied.

286 Preventive practices were generally well adhered to. Most participants reported consistently  
287 wearing face masks in public, a trend supported by global evidence (Chu et al., 2020). Social  
288 distancing was also widely practiced. However, handwashing compliance was less consistent,  
289 echoing previous findings that, despite widespread promotion, hand hygiene practices often  
290 fall short (Luby et al., 2021). The overall high practice scores in this study reflect a strong  
291 community commitment to following recommended health measures.

292 We acknowledge the limitations of the study. The serological tests were conducted towards the  
293 end of the pandemic and may have yielded different results compared to those performed at  
294 the peak of the outbreak. A larger sample size may have given a broader perspective on social  
295 variables such as employment status and other social factors investigated.

## 296 **Conclusions**

297 The prevalence of SARS-CoV-2 antibodies in Chililabombwe and Lusaka districts was  
298 estimated to be 11% and 8%, respectively. Both seropositive and seronegative participants  
299 demonstrated moderate knowledge and attitudes, as well as high levels of practice, which  
300 suggests a shared understanding of health risks and preventive measures of COVID-19. Lower  
301 knowledge, low attitudes and low practices were strongly associated with higher seropositivity.  
302 There is need to develop systems that incorporate various variables like climatic change and  
303 variability to enhance community engagement in future pandemics while monitoring the  
304 prevalence and dynamics of COVID-19 continuously.

## 305 **Acknowledgements**

306 We would like to express our sincere gratitude to SACIDS – Africa Centre of Excellence for  
307 Infectious Diseases, Sokoine University of Agriculture, Morogoro, Tanzania, for the invaluable

308 support. Special thanks also go to Dr. Chibeza Zulu, Mr. Andrew Mukubesa, Mr. Mwelwa  
309 Chembensofu, Mr. Patrick Katemangwe, and Mr. Penjaninge Kapila for their consistent  
310 technical assistance and collaborative brainstorming sessions. We are also grateful to the Mr  
311 Japhet Chiwaula of National Malaria Elimination Centre and the Ministry of Health for  
312 providing the essential facilities that greatly supported the data collection process.

### 313 **Funding**

314 This study was partially funded by the Africa Centre of Excellence for Infectious Diseases in  
315 Humans and Animals (ACEIDHA) project (grant number P151847) funded by the World Bank  
316 and the Strengthening SACIDS and Regional COVID-19 Emergency Preparedness in Eastern  
317 and Southern Africa (Agreement for award No 20-45012) funded by the Skoll Foundation.

### 318 **Declarations**

### 319 **Competing interests**

320 The authors declare no competing interests.

### 321 **References**

322 Adam M, Mohamoud J, Mohamood A, Mohamed A, Garba B, Dirie N. Seroprevalence of  
323 Anti-SARS-CoV-2 Antibodies in Bendir Region, Somalia. *Vaccines*. 2022;:1–11.

324 Agrahari R, Mohanty S, Vishwakarma K, Nayak SK, Samantaray D, Mohapatra S. Update  
325 vision on COVID-19: Structure, immune pathogenesis, treatment and safety assessment.  
326 *Sensors Int*. 2021;:1–9.

327 Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Hand hygiene in the COVID-19 era. *J Infect  
328 Public Health*. 2021;14(5):665–6.

329 Arnaldo P, Mabunda N, Young WP, Tran T, Siteo N, Chelene I, Ismeal N. Mozambican

- 330 Population: A Cross-Sectional Serologic Study in 3 Cities, July–August 2020. *Clin Infect Dis.*  
331 2022;:S285–93.
- 332 Aynalem YA, Yirgu R, Gebresilassie M. Knowledge, Attitudes, and Practices towards  
333 COVID-19 and associated factors among healthcare workers in Southern Ethiopia. *J Public*  
334 *Health Res.* 2021;10(1):123–30.
- 335 Ball-Rokeach SJ, Kim YC, Matei S. Storytelling neighborhood: Paths to belonging in diverse  
336 urban environments. *Commun Res.* 2001;28(4):392–428.
- 337 Basch CE, Basch CH, Hillyer GC, Jaime C. The role of schools in promoting health literacy in  
338 the context of COVID-19. *Prev Chronic Dis.* 2020;17:E53.
- 339 Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ. Physical distancing, face  
340 masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and  
341 COVID-19: a systematic review and meta-analysis. *Lancet.* 2020;395(10242):1973–87.
- 342 Clements JM. Knowledge and behaviors toward COVID-19 among US residents during the  
343 early days of the pandemic: Cross-sectional online questionnaire. *JMIR Public Health Surveill.*  
344 2020;6(2):e19161. doi:10.2196/19161.
- 345 Daka V. Seroprevalence and risk factors of toxoplasmosis in individuals attending  
346 Chipokotamayamba Clinic in Ndola, Zambia. 2014.
- 347 Dinnes J, Deeks JJ, Berhane S, Taylor M, Adriano A, Davenport C, Dittrich S, Emperador D,  
348 Takwoingi Y, Cunningham J, Beese S. Rapid, point-of-care antigen and molecular-based tests  
349 for diagnosis of SARS-CoV-2 infection. *Cochrane Database Syst Rev.* 2021;3.  
350 doi:10.1002/14651858.CD013705.pub2.
- 351 Geldsetzer P. Knowledge and perceptions of COVID-19 among the general public in the  
352 United States and the United Kingdom: A cross-sectional online survey. *Ann Intern Med.*

353 2020;173(2):157–60. doi:10.7326/M20-0912.

354 Hasan NIA, Abidin SZ, Ganggayah MD, Jamal NF, Aziz WNHWA. Knowledge, attitude and  
355 practices (KAP) theory towards preventive measures among Malaysians in early outbreak of  
356 COVID-19. *Malays J Public Health Med.* 2022;22(1):38–47.

357 Jacobs J, Kühne V, Lunguya O, Affolabi D, Hardy L, Vandenberg O. Implementing COVID-  
358 19 (SARS-CoV-2) rapid diagnostic tests in Sub-Saharan Africa: a review. *Front Med.*  
359 2020;7:557797.

360 Jones M, Green R, White S. Attitudinal determinants of compliance with public health  
361 guidelines during the COVID-19 pandemic. *Health Psychol Rev [Preprint]*. 2021.

362 Khan MA. COVID-19: A global challenge with old history, epidemiology and progress so far.  
363 *Molecules.* 2020;1(26).

364 Kontou PI. Antibody tests in detecting SARS-CoV-2 infection: A meta-analysis. *Diagnostics.*  
365 2020;:1–15.

366 Luby SP, Agboatwalla M, Feikin DR, Painter J, Billhimer W, Altaf A, Hoekstra RM. Effect of  
367 handwashing on child health: A randomised controlled trial. *Lancet.* 2021;366(9481):225–33.

368 Mak GC, Cheng PK, Lau SS, Wong KK, Lau CS, Lim WW. Evaluation of rapid antigen test  
369 for detection of SARS-CoV-2 virus. *J Clin Virol.* 2020;129:104500.  
370 doi:10.1016/j.jcv.2020.104500.

371 Mesina F, Mangahas C, Gatchalian EM, Ramos M, Torres R, Ariola S. Use of convalescent  
372 plasma therapy among hospitalized coronavirus disease 2019 (COVID-19) patients: A single-  
373 center experience. *MedRxiv.* 2021;:1–22.

374 Peeling RW, Olliaro P, Boeras DI, Fongwen N. Scaling up COVID-19 rapid antigen tests:  
375 promises and challenges. *Lancet Infect Dis.* 2021;21(9):e290–5. doi:10.1016/S1473-

376 3099(21)00048-7.

377 Peiris JSM, Lai ST, Poon LLM, Guan Y, Yam LYC, Lim W, Nicholls J, Yee WKS, Yan WW,  
378 Cheung MT, Cheng VCC, Chan KH, Tsang DNC, Yung RWH, Ng TK, Yuen KY. Coronavirus  
379 as a possible cause of severe acute respiratory syndrome. *Lancet*. 2003;361(9366):1319–25.  
380 doi:10.1016/S0140-6736(03)13077-2.

381 Reuben RC, Danladi MMA, Saleh DA, Ejembi PE. Knowledge, attitudes, and practices  
382 towards COVID-19: An epidemiological study in North-Central Nigeria. *J Community Health*  
383 [Preprint]. 2021;45(5):1091–8. doi:10.1007/s10900-020-00881-1.

384 Rubegwa BA. Seroprevalence and risk factors of bovine brucellosis in dairy and traditional  
385 cattle herds in Kibaha District of Tanzania [thesis]. 2015;1.

386 Schiavo R. *Health communication: from theory to practice*. 2nd ed. San Francisco: Jossey-  
387 Bass; 2014.

388 Smith A, Jones B, Thompson C. The impact of educational attainment on health literacy and  
389 its role in the prevention of COVID-19. *Public Health Rev* [Preprint]. 2020.


390 Theodore D, Branche A, ... LZ-J network, U. Clinical and demographic factors associated with  
391 COVID-19, severe COVID-19, and SARS-CoV-2 infection in adults: a secondary cross-  
392 protocol analysis of 4. *JAMA Netw Open*. 2023;:1–11.

393 Ugwu C, Adekola A, Fasoro O, Oyesola O, Heeney J, Happi C. Insights into the Nigerian  
394 COVID-19 outbreak. *Semantic Scholar*. 2020;:1–9.

395 Wei L, Zhang B, Lu J, Liu S, Chang Z, Peng C, Liu X. Characteristics of household  
396 transmission of COVID-19. *Clin Infect Dis*. 2020;:1943–6.

397 Zambia Statistics Agency. *The Census of Population and Housing*. 2022. Available from:  
398 <https://www.zamstats.gov.zm/> (Accessed 12 Dec 2023).

399 Zhong BL, Luo W, Li HM, Zhang QQ, Liu XG, Li WT, Li Y. Knowledge, attitudes, and  
400 practices towards COVID-19 among Chinese residents during the rapid rise period of the  
401 COVID-19 outbreak: a quick online cross-sectional survey. Int J Biol Sci. 2020;16(10):1745–  
402 52.



**Figure 1. Map of the Study Area**

**Table 1.** Socio-demographic characteristics and seroprevalence study participants

Variable	Categories	No.	No. positive (% , 95% CI)	p-value
Overall		179	17 (9.5, 6.0-14.7)	
District	Chililabombwe	91	10 (11.0, 6.1-19.1)	0.49
	Lusaka	88	7 (8.0, 3.9-15.5)	
Gender	Male	84	5 (6.0, 2.6-13.2)	0.13
	Female	95	12 (12.6, 7.4-20.8)	
Age group (Years)	18 – 29	94	10 (10.6, 5.9-18.5)	0.71
	30 – 39	48	3 (6.2, 2.1-16.8)	
	40 - 49	22	3 (13.6, 4.7-33.3)	
	Above 50	15	1 (6.7, 1.2-29.8)	
Marital status	Married	75	8 (10.7, 5.5-19.7)	0.12
	Single	102	8 (7.8, 4.0-14.7)	
	Widow/widower	2	1 (50.0, 9.5-90.5)	
Level of Education	College/University	60	2 (3.3, 0.9-11.4)	0.16
	Secondary	73	9 (12.3, 6.6-21.8)	
	Primary	37	4 (10.8, 4.3-24.7)	
	No education	9	2 (22.2, 6.3-54.7)	
Employment status	Employed	93	9 (9.7, 5.2-17.4)	0.93
	Unemployed	86	8 (9.3, 4.8-17.3)	


**Table 2.** Association of Knowledge, Attitude, and Practices with SARS-CoV-2 positivity.

<b>Explanatory variables</b>	<b>Percent of seropositive respondents (95% CI)</b>	<b>P-value</b>
<b>Knowledge</b>		
Low	20.0	0.003
Moderate	2.97	
High	16.28	
<b>Attitude</b>		
Low	22.22	0.002
Moderate	3.23	
High	9.76	
<b>Practices</b>		
Low	40.0	0.002
Moderate	6.25	
High	10.53	

medRxiv preprint doi: <https://doi.org/10.1101/2025.09.08.25335374>; this version posted September 12, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

**Table 3.** Participants knowledge on COVID-19

Variable	Levels	Frequency seropositive	of Proportion (%)	Score (%)	Frequency seronegative	Of Proportion (%)	Score (%)
<b>What is the causative agent for COVID-19?</b>	Bacteria	8	47.05		27	16.7	
	Virus	9	52.94	52.94*	135	83.33*	83.33
<b>Signs/ symptoms of COVID-19</b>	Coughing	6	35.3		81	50	
	Runny nose	9	52.9	30.78*	73	45.1	40.38*
	Headache	1	5.9		53	32.7	
	Fatigue	2	12.8		23	14.2	
	Fever	8	47		97	59.9	
<b>How can a person get COVID-19?</b>	Through handshake	6	35.2		53	32.7	30.03*
	Air droplets	3	17.6		47	29	
	Close contact with infected person	7	41.2	31.3*	46	28.4	
<b>Do you think COVID-19 can be cured?</b>	Yes	15	88.2	88.2*	123	75.9	75.9*
	No	2	12.8		39	24.1	
<b>How can COVID-19 be cured?</b>	Herbal remedies	0	0		14	8.6	
	Praying	1	5.9		2	1.2	
	By health personal	13	76.5	76.5*	117	72.2	72.2*
<b>Average score on knowledge of COVID-19</b>				55.94**			52.68**



medRxiv preprint doi: <https://doi.org/10.1101/2025.09.08.25335374>; this version posted September 12, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

**Figure 4.** Participant's source of information on COVID- 19. The number of respondents for seropositive and seronegative were 17 and 162 respectively.

**Table 4.** Participants attitude towards COVID-19.

Variable	Levels	Frequency seropositive	of Proportion (%)	Score (%)	Frequency seronegative	of Proportion (%)	Score (%)
Do you think you can get COVID-19?	Yes	13	76.47	76.47*	132	81.48	81.48*
	No	0	0		27	16.7	
	Maybe	4	23.53		3	1.85	
Do you know anyone in your community who had COVID-19?	Yes	6	35.29	35.29*	78	48.15	48.15*
	No	11	64.71*		84	51.85	
How would you feel if you were found that you have COVID-19?	Embarrassed	1	5.88	20.0*	3	1.85	26.42*
	Fear	3	17.65		52	32.09	
	Surprised	1	5.88		7	4.32	
	Sadness	5	29.41		36	22.22	
	Other	7	41.17		64	39.51	
Who would you talk to if you had COVID-19?	Parent	6	35.29	27.45*	33	20.37	21.91*
	Children	3	17.64		28	17.28	
	Doctor	5	29.41		57	35.19	
	Spouse	0	0		24	14.81	
	No one	3	17.65		20	12.35	
What worries you the most when you think of COVID-19?	Isolation	3	17.65	50*	29	17.90	31.48*
	Unemployment	0	0		11	6.79	
	Death	14	82.35		113	69.75	
	Other	0	0		9	5.55	
Average KAP score on Attitude of COVID-19				41.84**			41.89**

**Table 5.** Participants Practices towards COVID-19

Variable	Levels	Frequency seropositive	of Proportion (%)	Score (%)	Frequency seronegative	of Proportion (%)	Score (%)	
<b>Have you consistently followed the recommended guidelines for wearing masks in public places?</b>	Yes	13	76.47	76.47*	116	71.60	71.60*	
	No	0	0		1	0.62		
	Sometimes	4	23.53		45	27.78		
<b>How frequently do you wash your hands with soap and water as a preventive measure for COVID-19?</b>	Always	9	52.94	52.94*	96	59.26	59.26*	
	Frequently	2	11.76		22	13.58		
	Occasionally	6	35.29		44	27.16		
<b>In the past month, how often have you avoided large gatherings or crowded places to reduce the risk of COVID-19 transmission?</b>	Always	15	88.24	88.24*	135	83.33	83.33*	
	Frequently		0		23	14.19		
	Occasionally	2	11.76		4	2.47		
<b>Do you think we can prevent such a global pandemic in the future?</b>	Yes	10	58.82	58.82*	103	63.58	63.58*	
	No	0	0		9	5.55		
	Maybe	7	41.18		50	30.86		
<b>Average score on Practices of COVID-19</b>							69.12**	69.44**

% = Percentage; \* = Proportion considered as practice score, \*\*=Average practice score

medRxiv preprint doi: <https://doi.org/10.1101/2025.09.08.25335374>; this version posted September 12, 2025. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  
It is made available under a [CC-BY 4.0 International license](#) .